{
    "id": 29008,
    "fullName": "IRF2BP2 - NTRK1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "IRF2BP2-NTRK1 results from the fusion of IRF2BP2 and NTRK1 (PMID: 29466156). IRF2BP2-NTRK1 has been identified in thyroid cancer (PMID: 29466156, PMID: 29144541), lung adenocarcinoma (PMID: 28719467) and prostate adenocarcinoma (PMID: 31763365), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 14916,
                    "pubMedId": 29144541,
                    "title": "Genetic landscape of papillary thyroid carcinoma in the Chinese population.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29144541"
                },
                {
                    "id": 18350,
                    "pubMedId": 31763365,
                    "title": "Prostatic adenocarcinoma with novel NTRK3 gene fusion: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31763365"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                },
                {
                    "id": 12997,
                    "pubMedId": 28719467,
                    "title": "Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28719467"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 359948,
        "geneSymbol": "IRF2BP2",
        "terms": [
            "IRF2BP2",
            "CVID14"
        ]
    },
    "variant": "IRF2BP2 - NTRK1",
    "createDate": "11/27/2018",
    "updateDate": "03/23/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15290,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a combined analysis of three trials, Vitrakvi (larotrectinib) treatment resulted in complete response in two patients with advanced solid tumors harboring an IRF2BP2-NTRK1 fusion (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30932,
                "profileName": "IRF2BP2 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15271,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, NTRK1 G595R was identified at disease progression in a patient with thyroid cancer harboring IRF2BP2-NTRK1 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30933,
                "profileName": "IRF2BP2 - NTRK1 NTRK1 G595R"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30932,
            "profileName": "IRF2BP2 - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 19344,
                    "name": "Larotrectinib",
                    "profileName": "IRF2BP2 - NTRK1"
                }
            ]
        },
        {
            "id": 30933,
            "profileName": "IRF2BP2 - NTRK1 NTRK1 G595R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}